P
Prime Medicine, Inc. Common Stock (PRME)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$3.84
-0.35 (-8.35%)
Market Cap: $932.06M
Last updated: Nov 17, 2026 at 4:31 PM ET
Prime Medicine, Inc. Common Stock (PRME) Valuation Multiples
Prime Medicine, Inc. Common Stock (PRME) trades at 96.7x sales and 80.9x book value. Its P/S ranged from 33.6x in 2023 to 346.7x in 2022 across the 4 year ends with a P/S figure.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 96.7x |
| Price to book | 80.9x |
| PEG | N/A |
| FCF yield | -23.2% |
Valuation History
Over the 4 year ends shown, its P/B ranged from 2.3x in 2024 to 6.5x in 2023.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $3.47 | 105.1x | 4.3x |
| 2024 | $2.92 | 113.1x | 2.3x |
| 2023 | $8.86 | 33.6x | 6.5x |
| 2022 | $18.58 | 346.7x | 5.7x |
Frequently Asked Questions About PRME
What is PRME's price to sales ratio?
Prime Medicine, Inc. Common Stock has a price to sales ratio of 96.7x.
PRME pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors